Kornimate/medical-research-clean huggingface dataset:
omitting of lymphadenectomy is acceptable for lung cancer smaller than 6 mm in solid size

Conditions: Non-small Cell Lung Cancer

Summary: many studies suggested that selective lymph node sampling was acceptable for specific non-small cell lung cancer (nsclc). this study aimed to evaluate the acceptability of omitting of lymphadenectomy for selected nsclc. patients with small-sized (≤2 cm) nsclc who underwent surgical resection between 2009 and 2022 were retrospectively screened.

many studies suggested that selective lymph node sampling was acceptable for specific non-small cell lung cancer (nsclc). this study aimed to evaluate the acceptability of omitting of lymphadenectomy for selected nsclc. patients with small-sized (≤2 cm) nsclc who underwent surgical resection between 2009 and 2022 were retrospectively screened. the characteristics of patients with nodal metastasis were demonstrated. for selected patients, the perioperative and long-term outcomes of patients with and without lymphadenectomy were compared. log-rank test and cox regression analysis were adopted for prognostic evaluation. a total of 2713 nsclc patients were enrolled, and 75 of them (2.76%) had nodal involvement. none of patients with pure ground glass opacity (0/945) had nodal metastasis, while 14 patients with part-solid (14/1260, 1.11%) and 61 patients with solid nodules (61/508, 12.01%) had nodal involvement. patients with nodal metastasis had a minimum solid size of 6 mm. nsclc with solid components \< 6 mm (n=1588) had no nodal metastasis. of them, 339 patients underwent sublobar resection without lymphadenectomy (srn0), 1056 subjects received sublobar resection with lymphadenectomy (srn1), and 190 patients received lobectomy plus lymphadenectomy (lrn1). patients with srn0 had a shorter operating time, less volume of drainage, a lower incidence of chylothorax (0 vs. 0.6% vs. 2.1%, p=0.012) and air leakage, as well as a shorter postoperative hospitalization (3 vs. 4 vs. 4 days, p\<0.001) than those with srn1 or lrn1. during a median follow-up of 61 months, no patient with srn0 was dead or tumor recurrent. the 5-year recurrence-free survival was 100%, 99.2% and 98.5% for patients with srn0, srn1 and lrn1, respectively (p=0.370).

Eligibility criteria:
inclusion criteria: * pathologically confirmed non-small cell lung cancer (nsclc) * the maximum tumor diameter ≤2 cm * receiving surgical treatment between 2009-2022 exclusion criteria: * non-primary nsclc; * with small cell lung cancer components; * undergoing preoperative neoadjuvant therapies; * with compromised resection; * malignant tumor history over the past five years.

Keywords: sublobar resection non-small cell lung cancer no lymphadenectomy solid size
bronchial hyperreactivity in atopic dermatitis patients - a 10 year follow-up

Conditions: Atopic Dermatitis

Summary: the investigators will contact 64 patients with atopic dermatitis (ad) who participated in a long-term tacrolimus ointment trial in helsinki 10 years ago, and ask them to participate in this follow-up study. the investigators will do the same tests as 10 years ago, i.e. bronchial hyperreactivity, skin prick tests, serum-ige, mantoux-test (2 tu), and questionnaires about asthma and allergic rhinitis symptoms. the investigators also collect data about their ad medication during the last 10 years. the investigators hypothesis is that when the skin condition improves in patients with ad the brochial hyperreactivity improves. the investigators also want to study whether different treatments play a role in the development or resolution of bronchial hyperreactivity.

we will by letters and telephone contact all patients (n=64) who fulfill the inclusion criteria for this study. the testing in the study (bronchial hyperreactivity, skin prick testing, serum ige) is cross-sectional, but we retrospectively collect data from the last 10 years about the skin condition and medication for atopic diseases.

Eligibility criteria:
inclusion criteria: * patient has participated in the fg-506-06-21 study in helsinki * patient was tested for bronchial hyperreactivity in the years 1998-2000 * patient gives signed informed consent to participate in this study

Keywords: atopic dermatitis bronchial hyperreactivity skin prick tests serum ige mantoux test
evaluation of fusion™ vascular graft for above knee targets

Conditions: Peripheral Arterial Occlusive Disease (PAOD)

Summary: the purpose of the post-market study was to evaluate the safety and performance of the fusion vascular graft.

this study was a prospective, single-arm, multicenter study conducted in germany and austria to evaluate the fusion vascular graft in patients with peripheral arterial occlusive disease undergoing above-the-knee bypass. follow-up visits were performed at 30 days, 6 months, 12 months and included patency and post operative complications not associated with bypass patency.

Eligibility criteria:
inclusion criteria: * no known malignant disease * patient was willing and able to have follow-up visits and examinations * peripheral arterial occlusive disease (paod) requiring treatment of the femoral artery; fontaine stage iib, iii and iv with dry peripheral gangrene, and suitable for surgery * patient was not participating in other clinical trials that would conflict with this protocol * patient agreed to the study provisions and provided written informed consent exclusion criteria: * urgent or emergent surgery of any kind * documented acute or suspected systemic infection * life expectancy of less than one year * patients who had a minor or major stroke within 6 weeks of the procedure or who had evidence of prior massive stroke * patients who had experienced a myocardial infarction within 6 weeks prior to the procedure or had unstable angina pectoris * severe chronic renal insufficiency or undergoing hemodialysis * patients treated with coumadin (warfarin) that had not been stopped within 72 before enrollment * medical conditions requiring oral anticoagulation * antiplatelet therapy with clopidogrel or dual antiplatelet as well as any other antithrombotic medication within 7 days prior to scheduled bypass surgery except unfractionated heparin or aspirin * international normalized ratio (inr) \> 2.0 * known hypersensitivity to heparin * patient not tolerating aspirin * previous history of bypass surgery in the target limb * patient with category 6 ischemia (tissue loss) * acute limb ischemia of any grade (0-3) * patient with no outflow beyond the popliteal artery * pregnant or may become pregnant during the course of the study * uncontrolled arterial hypertension (bp \> 200 mmhg) at 2 successive readings * anaemia (hemoglobin \< 8 g/ml) * thrombocytopenia \< 50 g/l * active bleeding according to clinical judgment * infected wet gangrene of any size and location at the target limb * compromised arterial flow * patient unwilling or unable to comply with follow-up requirements
blood-sparing during hip prosthesis surgery with exacyl® in patients treated with rivaroxaban

Conditions: Blood Loss After a Total Hip Replacement

Summary: this study evaluates the efficacy of tranexamic acid versus placebo on perioperative blood loss using two dosage regimens (standard and extended) after a surgery during total hip arthroplasty in patients receiving the novel fast-acting oral anticoagulant rivaroxaban for prophylaxis of thrombosis.

in 2011, 140 000 total hip replacements were performed and bleeding remains one of the major complications responsible for significant morbidity. this study will evaluate a new treatment to prevent bleeding due to this surgery. indeed, the tranexamic acid (exacyl) will be used in two modes of administration (standard or extended) versus placebo combined with a rivaroxaban treatment at a dose of 10 mg / day for 35 days. patients will be randomized (exacyl standard vs exacyl extended vs. placebo) and will be followed for 3 months.

Eligibility criteria:
inclusion criteria: * over 18 years of age * scheduled to undergo elective non-traumatic primary cementless tha * having given written informed consent to participate in the trial * covered by social security exclusion criteria: * rapidly destructive arthrosis of the hip * history of prior surgery on the operative hip * contraindications to the use of tranexamic acid: * ischaemic artery disease (angina pectoris, myocardial infarction, acute coronary syndrome or stroke) * history of venous thromboembolism * severe renal impairment, i.e. with clearance \< 30ml/mn * epilepsy or history of convulsions * contraindications to the use of rivaroxaban * severe renal failure (clearance \<30ml / min) * cirrhotic patients with child pugh b * pregnancy and breastfeeding * cognitive disorder that precludes giving informed consent * refusal to participate in trial * allergy to either of the trial treatments * on-going prophylaxis of thrombosis using an agent other than rivaroxaban * on-going platelet aggregation inhibitor at a dose exceeding 125 mg daily

Keywords: hip replacement rivaroxaban exacyl blood loss
upnride power standing wheelchair for sci

Conditions: Spinal Cord Injuries

Summary: people with higher level of spinal cord injury have limitations to using exoskeletal-assisted walking devices due to restrictions of trunk stability, functional use of the upper extremities and hand grip. with increasing sedentary time in wheelchairs, people with sci have a high risk for developing secondary complications. a powered wheelchair has recently been developed for use in persons with spinal cord injury that provides a solution for placing the user in an upright, standing position while maintaining the overground mobility features of the powered wheelchair; providing the ability to engage in society in either a standing or seated position. the purpose of this study is to verify user performances of the upright powered wheelchair and to identify obstacles that are difficult, or prevent use. additionally, the option to have upright posture throughout the day may have the potential to improve some of the secondary medical conditions associated with the extreme sedentary lifestyle. this study will determine change from baseline after 12 weeks of use for safety, tolerance, medical, physical and quality of life outcomes. the intervention will consist of 3.5 hours per session, 3 times per week for 12 weeks. during each session, participants will be asked to stand at least 5 minutes during every 15 minutes. to our knowledge, there is no existing empirical data on intermittent standing during the day in persons with higher levels of sci who cannot otherwise stand and whether this approach will improve health related outcomes.


Eligibility criteria:
inclusion criteria: 1. power wheelchair user as a primary means of mobility; 2. 18-89 years old; 3. ≥1 year after sci; 4. height of 160 to 190 cm; 5. weight of \<100 kg; and 6. able to sign informed consent. exclusion criteria: 1. able to ambulate with or without an assistive device or physical assistance greater than 4 consecutive steps; 2. any pressure ulcer at any body location that is deemed to be contraindicated for a power wheelchair or standing frame by the study physician; 3. concurrent medical disease that would be exclusionary for standing (as per the clinical judgment of the study physician); 4. severe spasticity (ashworth 4) or uncontrolled clonus; 5. history of fragility fractures, long bone fractures in the past 1 years, heterotrophic ossification, or other bone conditions that would be exclusionary for use of a standing modality as per the clinical judgment of the study physician; 6. significant contractures that would be exclusionary for use of a standing modality as per the clinical judgment of the study physician 7. psychiatric or cognitive status that may interfere with the ability to follow instruction to use the device; and 8. pregnant or lactating women.
safety and efficacy of mp-424 to treat chronic hepatitis c

Conditions: Hepatitis C

Summary: the purpose of this study is to assess the efficacy and safety after administration of mp-424 to patients with chronic hepatitis c.


Eligibility criteria:
inclusion criteria: * patients diagnosed with genotype 1b chronic hepatitis c * patients naive to the concomitant medications with interferon exclusion criteria: * patients diagnosed with decompensated cirrhosis * patients diagnosed with positive hbs antigen in the test

Keywords: chronic hepatitis c protease inhibitor
high-intensity interval training in patients with post-acute coronary syndrome

Conditions: Acute Coronary Syndrome; Arrhythmia

Summary: to date, no studies have evaluated the safety or efficiency (improvement of maximal oxygen uptake \[vo2peak\]) of a high-intensity interval training (hiit) program in post-acute coronary syndrome (post-acs) patients. heart rate variability (hrv) and recovery (hrr), qt dispersion (qtd) and ventricular arrhythmias are all indices associated with an increased risk of cardiac death. hiit has been shown to improve these risk markers and be safe in coronary heart disease patients but not yet in post-acs patients which are considered more at risks. the aim of this study was to compare a hiit program to a moderate-intensity continuous exercise training (micet) program on hrv, hrr, qtd parameters and occurrence of ventricular arrhythmias in post-acs patients.


Eligibility criteria:
inclusion criteria: * males or females aged ≥ 18 years * acute coronary syndrome within 6 weeks (unstable angina, or non-st elevation myocardial infarction (nstemi), or st elevation myocardial infarction (stemi with the presence of 2/3 criteria (i.e. typical chest pain, electrocardiographic ischemic change or elevated troponin t * complete revascularization defined as no major epicardial coronary artery or bypass graft with a residual diameter stenosis \>50% and no residual left main stenosis ≥40% * left ventricular ejection fraction \>40% * stable doses of medication during the 4 weeks prior to enrolment (stemi patients must be on a stable dose of beta-blocker) * able to perform a maximal cardiopulmonary exercise test, 7) capacity and willingness to sign informed consent. exclusion criteria: * recent coronary bypass surgery (\<6 months) * incomplete revascularisation, left ventricular ejection fraction \<40% * significant valvular disease (mitral stenosis, moderate to severe mitral insufficiency, aortic stenosis, or aortic insufficiency) * uncontrolled hypertension (systolic blood pressure/diastolic blood pressure \>180/110 mmhg) * significant resting electrocardiogram abnormalities (left bundle branch block, non-specific intraventricular conduction delay, left ventricular hypertrophy, resting st-segment depression) * chronic atrial fibrillation * pacemaker or implantable cardioverter defibrillator * low functional capacity (\<5 basal metabolic equivalent of task \[mets\]) * change of cardiac medications within 4 weeks of enrolment and any contraindication to exercise testing or exercise training.

Keywords: interval training autonomic nervous system post-acute coronary syndrome
functional electrical stimulation use in trans-tibial amputations

Conditions: Traumatic Amputation of Lower Extremity

Summary: the purpose of this study is to demonstrate the efficacy of functional electrical stimulation (fes) for trans-tibial amputees. the investigators aim to demonstrate that providing three months of fes intervention will increase knee extension strength, increase volume of the residual limb and decrease chronic and phantom pain.

summary study goals: the purpose of this study is to demonstrate the efficacy of fes for trans-tibial amputees. the investigators aim to demonstrate that providing three months of fes intervention will increase knee extension strength, increase volume of the residual limb and decrease chronic and phantom pain. experimental design: randomized control trial methods: twenty participants will be recruited and randomly divided into two groups, one group will receive the fes intervention while the other group will continue with activities of daily living. both groups will keep a daily log of number of hours the prosthesis is worn, number of hours the fes is worn (if used) and any changes in skin conditions or medications. both groups will return for assessment visits at 4, 8, and 12 weeks and a follow up visit 3 months post-intervention for investigators to inspect the residual limb and check the fit of the prosthetic socket, record residual limb knee extension strength on the biodex machine, take measurements (circumferences and lengths) of the residual limb with a tape measure and ruler, scan the limb with the hand held three-dimensional motion-tracking laser scanner system and the participant will be asked to complete a pain questionnaire. the prosthetic evaluation questionnaire (peq) will be completed at the 12 week and the 3 month follow-up visits. although outcomes data were captured during each assessment visit (0, 4, 8 and 12 weeks and 3 months), changes in the primary outcomes (strength, volume and pain) at timepoints 0 weeks (pre-intervention) and 12 weeks (post- intervention) were of primary interest.

Eligibility criteria:
inclusion criteria: * men and women over 18 years of age. * participants have a unilateral trans-tibial amputation with a minimum of a 4" residual limb. this length of amputation was chosen to provide for adequate surface area for the electrodes. * participants must be a minimum of two years postoperative to insure proper healing of the limb has occurred. * participants have chronic limb pain. * no prior experience in using tens or fes. exclusion criteria: * no cardiac conditions, such as hypertension, congestive heart failure, or a pacemaker. * people with severe diabetes who have insensate skin and or neuropathy.
the safety and effectiveness of isoprinosine in patients with weakened immune systems and lymph node disease

Conditions: Lymphatic Disease; HIV Infections

Summary: the objective of this phase iii, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunological parameters: * increase in natural killer (nk) cell activity. * increase in total t-cells (okt-11). * increases in absolute number and percentage of t-helper cells (okt-4).


Eligibility criteria:
exclusion criteria co-existing condition: patients with the following are excluded: * history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction and severe gastric ulcer. * lymphoid malignancy. * infectious mononucleosis caused by cytomegalovirus or epstein-barr virus. * heart disease (especially if receiving cardiac glycosides). * hemophilia. patients with the following are excluded: * kaposi's sarcoma or overt opportunistic infections as follows: * candida albicans, pneumocystis carinii, herpes simplex, cryptococcus neoformans, histoplasma capsulatum, mycobacterium avium-intracellulare, toxoplasma gondii, legionella, cryptosporidium, isospora, and papovavirus. * active evidence of infectious mononucleosis caused by epstein-barr virus (ebv) or cytomegalovirus (cmv) as determined by heterophil test (ebv) or cell culture (cmv). * history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer. * critical illness. * condition requiring hospitalization. * women of childbearing age are excluded. * hemophilia. prior medication: excluded: * steroids. * cytotoxic immunosuppressive agents. * antiviral medicine. prior treatment: excluded: * radiotherapy. patients who have unexplained immunodepression and are at risk of developing aids. * patients with prolonged generalized lymphadenopathy for 3 or more months (greater than 1 cm at two or more noncontiguous sites). iv drug abuse.

Keywords: t-lymphocytes immune tolerance inosine pranobex killer cells t-lymphocytes, helper-inducer acquired immunodeficiency syndrome aids-related complex
diagnostic performance of fractional flow reserve derived from coronary ct angiography

Conditions: Coronary Artery Disease

Summary: this is a blind evaluation, self-control, multicenter clinical trial designed to determine the diagnostic performance of ct-ffr from coronary computed tomographic angiography (ccta), as compared to ccta alone, for non-invasive diagnosis of the presence of a hemodynamically significant coronary stenosis, using invasive fractional flow reserve (ffr) as the reference standard.


Eligibility criteria:
inclusion criteria: * age≥ 18 years old; * subjects with clinical need and consent for coronary angiography; * can provide the results of coronary ct angiography within 60 days prior to ica or agree to undergo coronary ct angiography; * the subjects knew about the experiment and signed the informed consent voluntarily. exclusion criteria: * patients who have had percutaneous coronary intervention (pci); * patients who had cabg; * acute coronary syndrome, such as acute st segment elevation; * severe tachycardia or arrhythmia; * patients with severe hepatorenal insufficiency; * patients with congenital heart disease, implanted pacemaker or defibrillator, artificial heart valve; * failure to perform invasive ffr examination or obtain ffr value due to various reasons; * allergic to β - blockers, nitrates and adenosine, sick sinus syndrome, long qt syndrome, severe hypotension, severe asthma, severe copd or copd; * persistent or significant clinical instability, including acute chest pain (sudden onset), cardiogenic shock, blood pressure instability (systolic blood pressure \< 90mmhg) and severe congestive heart failure (according to the heart classification of the new york heart association, grade iii or iv of cardiac function) or acute pulmonary edema; * the cta images of coronary artery showed that the stenosis rate was less than 30% or greater than 90%, or the diameter of diseased segment was less than 2.0mm; * ct-ffr can not be calculated because of the quality of cta image; * known pregnant and lactating women; * having participated in other clinical trials within 3 months; * other situations that the researchers judged were not suitable for inclusion.